The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GI Malignancies Debate 2023 - Chicago | How can ctDNA analysis aid in the management of gastrointestinal cancers?
Suneel Kamath, MD, Cleveland Clinic, Cleveland, OH, talks on the role of ctDNA analysis in the management of gastrointestinal cancers. Results from the Phase II DYNAMIC trial showed the benefits of using ctDNA analysis to predict risk of recurrence in patients with resected stage 2 colon cancer. The study reported that patients who were ctDNA-negative after resection had a low risk of recurrence and therefore could avoid undergoing adjuvant chemotherapy without negatively impacting outcomes. This was highly beneficial as these patients were able to avoid the toxicities associated with chemotherapy. Dr Kamath also highlights the potential of ctDNA analysis in screening programs, especially in younger populations. This interview took place at the Great Debates and Updates GI Malignancies Debate in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
